{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:09:41Z","timestamp":1790766581650,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.08.025","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T01:54:48Z","timestamp":1631152488000},"page":"262-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adherence to PARP inhibitor therapy among women with ovarian cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Haley A.","family":"Moss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.08.025_bb0005","article-title":"Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology","author":"Morgan","year":"2018","journal-title":"JNCCN"},{"key":"10.1016\/j.ygyno.2021.08.025_bb0010","author":"Cancer Control"},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.025_bb0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.ygyno.2021.08.025_bb0020","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0025","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.08.025_bb0030","unstructured":"IBM 2020 MarketScan Research Databases - Overview. Published October 20, 2020. (Accessed November 20, 2020). https:\/\/www.ibm.com\/products\/marketscan-research-databases."},{"issue":"7","key":"10.1016\/j.ygyno.2021.08.025_bb0035","first-page":"457","article-title":"Measuring concurrent adherence to multiple related medications","volume":"15","author":"Choudhry","year":"2009","journal-title":"Am. J. Manag. Care"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.025_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","article-title":"The assessment of refill compliance using pharmacy records: methods, validity, and applications","volume":"50","author":"Steiner","year":"1997","journal-title":"J. Clin. Epidemiol."},{"issue":"23","key":"10.1016\/j.ygyno.2021.08.025_bb0055","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.2018.19271","article-title":"Michael Interventions to Improve Medication Adherence: A Review","volume":"320","author":"Kini","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.025_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.025_bb0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.88.3.229","article-title":"Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study","volume":"88","author":"Wei","year":"2002","journal-title":"Heart."},{"issue":"83","key":"10.1016\/j.ygyno.2021.08.025_bb0070","first-page":"231","article-title":"Adherence to targeted oral anticancer medications","volume":"15","author":"Geynisman","year":"2013","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0075","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.08.025_bb0080","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.18553\/jmcp.2019.25.10.1125","article-title":"A comprehensive review of methods to measure oral oncolytic dose intensity using retrospective data","volume":"25","author":"Slejko","year":"2019","journal-title":"JMCP"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.025_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1740774513512565","article-title":"Adherence reporting in randomized controlled trials","volume":"11","author":"Zhang","year":"2014","journal-title":"Clinical Trials"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0090","first-page":"10","article-title":"Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review","volume":"21","author":"Banning","year":"2012","journal-title":"Eur. J. Cancer Care"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.2016.68.2807","article-title":"Association between out-of-pocket costs, race\/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer","volume":"35","author":"Farias","year":"2016","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0105","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2006.10.1022","article-title":"Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer","volume":"26","author":"Owusu","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.025_bb0110","author":"Meeting Library"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.025_bb0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cncr.31050","article-title":"Adherence to tyrosine kinase inhibitors among medicare part D beneficiaries with chronic myeloid leukemia","volume":"124","author":"Shen","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"JCO"},{"issue":"36","key":"10.1016\/j.ygyno.2021.08.025_bb0125","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.025_bb0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2020.12.015","article-title":"Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients","volume":"160","author":"Liang","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.025_bb0135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost?","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0140","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1200\/JOP.2017.027896","article-title":"Use of charity financial assistance for novel oral anticancer agents","volume":"14","author":"Olszewski","year":"2018","journal-title":"JOP"},{"key":"10.1016\/j.ygyno.2021.08.025_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3110-2","article-title":"Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists","volume":"17","author":"Timmers","year":"2017","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.08.025_bb0150","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/AOG.0000000000004170","article-title":"Adherence to oral anticancer therapeutics in the gynecologic oncology population","volume":"136","author":"Watson","year":"2020","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2021.08.025_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2018.19271","article-title":"Interventions to improve medication adherence: a review","author":"Kini","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.025_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2013.07.004","article-title":"Adherence enhancing interventions for oral anticancer agents: a systematic review","volume":"40","author":"Mathes","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0165","first-page":"380","article-title":"A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes","volume":"16","author":"Macintosh","year":"2007","journal-title":"Eur. J. Cancer Care"},{"issue":"4","key":"10.1016\/j.ygyno.2021.08.025_bb0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjqcco\/qcw018","article-title":"The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review","volume":"2","author":"Gandapur","year":"2016","journal-title":"Eur. Heart J. Qual. Care. Clin. Outcomes"},{"issue":"8","key":"10.1016\/j.ygyno.2021.08.025_bb0175","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:32Z","timestamp":1758772712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013238"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to PARP inhibitor therapy among women with ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}